Children with treatment-resistant epilepsy may soon have access to a fundamentally different therapeutic approach that targets the genetic root of seizure disorders rather than simply suppressing symptoms. This represents a potential shift from broad-spectrum anticonvulsants to precision medicine tailored to specific genetic mutations. The antisense oligonucleotide zorevunersen demonstrated meaningful seizure reduction in pediatric patients with Dravet syndrome, a severe form of epilepsy caused by mutations in the SCN1A gene. In the randomized controlled trial, patients receiving the experimental drug experienced significantly fewer convulsive seizures compared to those on placebo, with some achieving greater than 50% reduction in seizure frequency. The mechanism involves binding to specific RNA sequences to restore proper sodium channel function at the cellular level. This genetic targeting approach could revolutionize treatment for the estimated 1 in 15,000 children born with Dravet syndrome, who typically face lifelong disability from frequent, prolonged seizures that resist conventional medications. The technology behind zorevunersen builds on decades of antisense research, but represents one of the first successful applications to pediatric neurological disorders. While the results appear promising, several factors temper immediate enthusiasm. The study population was relatively small, and long-term safety data in developing brains remains limited. Additionally, the complex manufacturing process and specialized delivery requirements may initially restrict access. Most critically, this remains a single study requiring replication across larger, more diverse patient populations. Nevertheless, the precision medicine approach validated here could accelerate similar treatments for other genetic epilepsies affecting thousands of families worldwide.